Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Daily vitamin d may slash lung risks in kids with sickle cell disease

NCT ID NCT04170348

Disease control Sponsor: Columbia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether taking vitamin D every day could reduce lung complications in children and teens with sickle cell disease. Lung problems like infections, asthma attacks, and acute chest syndrome are major causes of illness and death in this condition. Researchers gave daily or monthly vitamin D3 or a placebo to 58 participants aged 3-20 to see if it lowered the rate of these respiratory events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vitamin D3 (cholecalciferol)
What this could lead to
If it works, daily vitamin D could become a simple, low-cost way to cut the risk of serious lung problems in children with sickle cell disease.
What could go wrong
This is a small Phase 2 trial with only 58 participants, so results may not apply to everyone. Vitamin D is generally safe, but high doses can cause side effects like high calcium levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

58 people

The number who actually took part.

Started

Sep 2020

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

3 to 20 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of sickle cell disease (Hb SS, Hb SC, Hb S-Beta-thalassemia) 2. Age 3-20 years old Exclusion Criteria: 1. Patient unwilling or unable to provide written informed consent (and assent, if applicable) 2. Patient unable or unwilling to comply with requirements of the clinical trial 3. Participation in another clinical trial 4. Current diagnosis of rickets 5. History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia 6. Current use of corticosteroids, excluding inhaled steroids 7. Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine) 8. Therapy with thiazide diuretics or lithium carbonate 9. Known liver or renal disease 10. Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry 11. Patients on chronic red blood cell transfusion therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute chest syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute chest syndrome asthma familial hemolytic anemia lung disorder nutritional disorder Respiration Disorders respiratory system disorder respiratory tract infectious disorder sickle cell disease vitamin D deficiency vitamin deficiency disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute chest syndrome Anemia, hemolytic, congenital Anemia, sickle cell Asthma Deficiency diseases vitamin Lung diseases Nutrition disorders Respiration disorders Respiratory tract diseases Respiratory tract infections Sickle cell disease Vitamin D deficiency

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.